Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination

Several inhibitors of programmed cell death-1 (PD-1) and programmed death ligand-1 (PD-L1) have been approved as a form of immunotherapy for multiple cancers. Ionizing radiation therapy (RT) has been shown to enhance the priming and effector phases of the antitumor T-cell response rendering it an at...

Descripción completa

Detalles Bibliográficos
Autores principales: Gong, Jun, Le, Thang Q., Massarelli, Erminia, Hendifar, Andrew E., Tuli, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987486/
https://www.ncbi.nlm.nih.gov/pubmed/29866197
http://dx.doi.org/10.1186/s40425-018-0361-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5987486/
https://www.ncbi.nlm.nih.gov/pubmed/29866197
http://dx.doi.org/10.1186/s40425-018-0361-7

Ejemplares similares